iBio (IBIO) Competitors $0.93 -0.03 (-3.07%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.92 -0.01 (-0.91%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IBIO vs. MNOV, COEP, IMMX, SLGL, ALXO, ANL, KPTI, IZTC, CUE, and HOWLShould you be buying iBio stock or one of its competitors? The main competitors of iBio include MediciNova (MNOV), Coeptis Therapeutics (COEP), Immix Biopharma (IMMX), Sol-Gel Technologies (SLGL), ALX Oncology (ALXO), Adlai Nortye (ANL), Karyopharm Therapeutics (KPTI), Invizyne Technologies (IZTC), Cue Biopharma (CUE), and Werewolf Therapeutics (HOWL). These companies are all part of the "pharmaceutical products" industry. iBio vs. Its Competitors MediciNova Coeptis Therapeutics Immix Biopharma Sol-Gel Technologies ALX Oncology Adlai Nortye Karyopharm Therapeutics Invizyne Technologies Cue Biopharma Werewolf Therapeutics iBio (NYSE:IBIO) and MediciNova (NASDAQ:MNOV) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership. Do institutionals and insiders have more ownership in IBIO or MNOV? 7.9% of iBio shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 0.6% of iBio shares are owned by insiders. Comparatively, 13.6% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is IBIO or MNOV more profitable? MediciNova's return on equity of -23.12% beat iBio's return on equity.Company Net Margins Return on Equity Return on Assets iBioN/A -73.15% -45.51% MediciNova N/A -23.12%-21.85% Do analysts prefer IBIO or MNOV? iBio currently has a consensus price target of $5.00, indicating a potential upside of 435.62%. MediciNova has a consensus price target of $7.00, indicating a potential upside of 469.11%. Given MediciNova's stronger consensus rating and higher possible upside, analysts clearly believe MediciNova is more favorable than iBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iBio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00MediciNova 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has more volatility and risk, IBIO or MNOV? iBio has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Does the media favor IBIO or MNOV? In the previous week, MediciNova had 2 more articles in the media than iBio. MarketBeat recorded 4 mentions for MediciNova and 2 mentions for iBio. MediciNova's average media sentiment score of 0.98 beat iBio's score of 0.20 indicating that MediciNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MediciNova 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, IBIO or MNOV? MediciNova has higher revenue and earnings than iBio. MediciNova is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiBio$375K48.93-$24.91M-$1.74-0.54MediciNova$1MN/A-$11.04M-$0.25-4.92 SummaryMediciNova beats iBio on 12 of the 14 factors compared between the two stocks. Get iBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBIO vs. The Competition Export to ExcelMetriciBioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$18.35M$934.71M$5.87B$21.69BDividend YieldN/A4.84%5.68%3.47%P/E Ratio-0.541.1074.5229.69Price / Sales48.9326.70548.3370.32Price / CashN/A19.5637.5625.00Price / Book0.666.6912.164.58Net Income-$24.91M-$4.50M$3.28B$1.00B7 Day Performance11.80%8.75%0.87%0.65%1 Month Performance28.05%9.50%4.96%3.07%1 Year Performance-51.13%22.47%60.74%14.34% iBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBIOiBio1.8987 of 5 stars$0.93-3.1%$5.00+435.6%-50.9%$18.35M$375K-0.54100Short Interest ↑Gap DownMNOVMediciNova2.3744 of 5 stars$1.31-2.2%$7.00+434.4%-37.9%$64.25M$1M-5.2410COEPCoeptis Therapeutics0.9052 of 5 stars$13.32+5.2%N/A+244.0%$64.23MN/A-2.302Positive NewsIMMXImmix Biopharma2.953 of 5 stars$2.22-3.1%$7.00+215.3%+15.8%$64.01MN/A-2.889News CoverageAnalyst ForecastShort Interest ↑SLGLSol-Gel Technologies0.7724 of 5 stars$22.79+4.1%N/A+290.9%$63.49M$11.54M-18.5350Analyst UpgradeShort Interest ↑ALXOALX Oncology3.7944 of 5 stars$1.17+2.6%$3.30+182.1%-50.5%$62.65MN/A-0.5340News CoveragePositive NewsANLAdlai Nortye1.9807 of 5 stars$1.69+0.9%$9.00+432.5%-8.7%$62.36M$5M0.00127News CoveragePositive NewsShort Interest ↓KPTIKaryopharm Therapeutics3.8829 of 5 stars$7.11-7.4%$34.00+378.2%-41.6%$61.65M$145.24M-0.49380Positive NewsIZTCInvizyne TechnologiesN/A$9.70flatN/AN/A$60.64MN/A0.0029News CoverageGap DownCUECue Biopharma2.7157 of 5 stars$0.78-2.7%N/A+27.8%$59.96M$9.29M-1.3960Positive NewsHOWLWerewolf Therapeutics3.9804 of 5 stars$1.31-5.8%$8.00+510.7%-33.8%$59.90M$1.88M-0.8040 Related Companies and Tools Related Companies MNOV Alternatives COEP Alternatives IMMX Alternatives SLGL Alternatives ALXO Alternatives ANL Alternatives KPTI Alternatives IZTC Alternatives CUE Alternatives HOWL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:IBIO) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
